

45th PLENARY MEETING OF THE SCIENTIFIC PANEL ON DIETETIC PRODUCTS, NUTRITION AND ALLERGIES

Meeting dates: 28-29 February -1 March 2012
Venue: EFSA, **Via Carlo Magno 1/a**, Parma, 43126

Draft Agenda

#	Items
1	Welcome, apologies for absence
2	Adoption of the agenda of this Plenary meeting & the minutes of the previous Plenary meeting
3	Declarations of interest
4	Feedback from EFSA Scientific Committee and other EFSA Panels, and general information from EFSA
5	Feedback from the Commission on matters relating to the Panel
6	New requests
7	General issues on health claims evaluations 7.1 Update on Article 13(5) and 14 applications 7.2 Draft guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations (EFSA-Q-2010-01183) - <i>For discussion</i> 7.3 Technical report: Outcome of a public consultation on the Draft guidance on the scientific requirements for health claims related to appetite ratings, weight management, and blood glucose concentrations (EFSA-Q-2011-00307) -<i>For endorsement</i>
8	Applications pursuant to Article 14/13(5) of Regulation (EC) No 1924/2006 - <i>For discussion/ possible adoption</i> 8.1 <i>Extraction Purification Innovation France</i> - “Wheat polar lipid extract” and “improved skin hydration” (Art. 13(5): 0315_FR; EFSA-Q-2011-01122) 8.2 <i>Pierre Fabre Dermo-Cosmétique–Iron</i> and “maintenance of normal hair growth” (Art 13(5): 0320_FR; EFSA-Q-2012-00059)

- 9 **Further assessment of Article 13 list claims - *For discussion/ possible adoption***
- 9.1. **Dried prunes & bowel function** (ID 1164 - EFSA-Q-2012-00161)
 - 9.2. **Lutein & vision** (ID 1603-EFSA-Q-2012-00162; ID 1604-EFSA-Q-2012-00163)
 - 9.3. **Alpha-cyclodextrin & post-prandial glycaemic responses** (ID 2926-EFSA-Q-2012-00172)
 - 9.4. **Soy isoflavones & bone mineral density** (ID 1655 - EFSA-Q-2012-00166)
 - 9.5. **Soy isoflavones & vasomotor symptoms associated with menopause** (ID 1654-EFSA-Q-2012-00165; 1704-EFSA-Q-2012-00167; 2140-EFSA-Q-2012-00170; 3093-EFSA-Q-2012-00212; 3154-EFSA-Q-2012-00213; 3590-EFSA-Q-2012-00214)
 - 9.6. **“*L. rhamnosus* CNCM I-1720 and *L. helveticus* CNCM I-1722”** (ID 939- EFSA-Q-2012-00131)
 - 9.7. ***Saccharomyces boulardii* CNCM I-1079** (ID 913 - EFSA-Q-2012-00127)
 - 9.8. **Vitamin K & function of the heart and blood vessels** (ID 125 - EFSA-Q-2012-00125)
- 10 **Infant Formulae - *For discussion/ possible adoption***
- 10.1 **Goat's milk protein as a protein source for infant formulae and follow-on formulae** (EFSA-Q-2011-00132)
- 11 **Novel Foods - *For discussion***
- 11.1 **Bioreal AB-Astaxanthin** (EFSA-Q-2011-00990)
 - 11.2 **Friesland Campina Domo B.V.-Bovine Lactoferrin** (EFSA-Q-2010-01269)
 - 11.3 **Moringa Milk Industry Co Ltd-Bovine Lactoferrin** (EFSA-Q-2011-00974)
- 11 **Any other business**